BioSpace News Archive

Results from randomized phase II CONDOR trial suggest the immune checkpoint blocker is safe and shows encouraging anti-tumor activity as second-line treatment in tumors with low/negative PD-L1; no difference in clinical activity observed between durvalumab alone or in combination with tremelimumab [13-February-2018] SCOTTSDALE, Ariz., Feb. 13, 2018 /PRNewswir

This strategic approach is employed in an effort to capitalize on opportunities to increase sales across indications for the same medication.

Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.

Thirty-four of 35 patients in the trial experienced a reduction in tumor size following treatment with the targeted kinase inhibitor.

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the HPV, including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially.

Strong momentum from 2017 fuels strong start for Athenex in 2018.

On 15 August 2017, Ossur initiated a share buy-back program.

Dynasil Corporation of America today announced revenue of $9.2 million for the first quarter of fiscal year 2018.

The new DKT-Dahua partnership will expand the availability, accessibility, and affordability of Levoplant for the women who need it most.

The test enables laboratories to simultaneously assess Factor II and Factor V gene mutations from a single patient sample.